Revolution Medicines, Inc. · NASDAQ:RVMD

Revolution Medicines — Technical Presentation (July 2026)

15 slides from Revolution Medicines's technical presentation, July 2026

  1. Slide 1: Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Chemotherapy in Patients With 1L RAS G12D mPDAC

    Abstract 635 Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Chemotherapy in Patients (Pts) With 1L RAS G12D Metastatic Pancreatic Adenocarcinoma (mPDAC) Brian M. Wolpin,* Shubham Pant, Alexander Spira, Tiago Biachi De Castria, Gregory P. Botta, Vaia Florou, Gulam A. Manji, Arsen Osipov, Meredith

  2. Slide 2: Declaration of Interests

    Declaration of Interests Brian M. Wolpin • I have the following relevant financial relationships to disclose: Employee of: Dana-Farber Cancer Institute, Boston, MA, USA Consultant for: Agenus, BeiGene, BMS/Mirati, Cancer Panels, EcoR1 Capital, GRAIL, Harbinger Health, Immuneering, Ipsen, Lustgarten

  3. Slide 3: Large Unmet Need in RAS G12D Mutant Cancers

    Large Unmet Need in RAS G12D Mutant Cancers Uncontrolled RAS(ON) Signaling Drives Cells to an Oncogenic State1-3 Normal RAS Cancer Mutations • PDAC is a RAS-driven disease, with 40% of patients harboring a KRAS G12D mutation4 • Patients with RAS G12D mutant mPDAC are reported to have an Cell Membran

  4. Slide 4: Zoldonrasib Is an Oral, Mutant-Selective Covalent Inhibitor Targeting the ON State of RAS G12D

    Zoldonrasib Is an Oral, Mutant-Selective Covalent Inhibitor Targeting the ON (Active, GTP-Bound) State of RAS G12D Zoldonrasib Mechanism of Action Zoldonrasib Zoldonrasib (RMC-9805) RAS(ON) RAS(ON) Inhibitory Tri-Complexes RAS(ON) G12D-Selective • Mutant-selective covalent inhibitor of RAF (RBD-CRD)

  5. Slide 5: RMC-GI-102 Platform Study (NCT06445062)

    RMC-GI-102 Platform Study (NCT06445062) Key Eligibility Criteriaa Part 1: Dose Escalation • Metastatic PDAC with RAS G12D mutations Zoldonrasib Modified + Part 2: Dose Expansion • No prior systemic therapy for metastatic 1200 mg QD FOLFIRINOXb disease • ECOG PS 0–1 Zoldonrasib Gemcitabine + • Patien

  6. Slide 6: Demographics and Baseline Characteristics

    Demographics and Baseline Characteristics Zoldonrasib 1200 mg QD Zoldonrasib 1200 mg QD + mFFX + GnP (N=41) (N=40) Age, median (range), years 62 (40–83) 69 (36–83) Male, n (%) 23 (56) 24 (60) ECOG PS 1, n (%) 27 (66) 22 (55) Liver metastases at baseline, n (%) 36 (88) 26 (65) Metastatic at diagnosis

  7. Slide 7: Treatment-Related Adverse Events With Zoldonrasib + mFFX

    Treatment-Related Adverse Events With Zoldonrasib + mFFX in 1L RAS G12D PDAC Zoldonrasib 1200 mg QD + mFFX (N=41) Any Grade Grade ≥3 Any study drug-related AE, n (%) 40 (98) 25 (61) TRAEs occurring in ≥20% of all patients, n (%) • TRAEs broadly consistent with the Diarrhea 32 (78) 4 (10) established

  8. Slide 8: Treatment-Related Adverse Events With Zoldonrasib + GnP

    Treatment-Related Adverse Events With Zoldonrasib + GnP in 1L RAS G12D PDAC Zoldonrasib 1200 mg QD + GnP (N=40) Any Grade Grade ≥3 Any study drug-related AE, n (%) 40 (100) 32 (80) TRAEs occurring in ≥20% of all patients, n (%) Fatigue 32 (80) 10 (25) Nausea 28 (70) 1 (3) • TRAEs broadly consistent

  9. Slide 9: Dose Modification Due to TRAEs and Dose Intensity of Zoldonrasib + Chemotherapy

    Dose Modification Due to TRAEs and Dose Intensity of Zoldonrasib + Chemotherapy in 1L RAS G12D PDAC Zoldonrasib 1200 mg QD + mFFX Zoldonrasib 1200 mg QD + GnP (N=41) (N=40) Zoldonrasib mFFX Zoldonrasib GnP Dose modification, n (%)a Dose interruption 15 (37) 24 (59) 14 (35) 30 (75) Dose reduction 7 (

  10. Slide 10: ORR and DCR With Zoldonrasib + mFFX

    ORR and DCR With Zoldonrasib + mFFX in 1L RAS G12D PDAC Zoldonrasib 1200 mg QD + mFFXa (N=22) ORR (95% CI), %b 82 (60–95) DCR (95% CI), %c 96 (77–100) • PFS and OS estimates remain immature due to limited follow-up at time of DCO Data cutoff: 8 Feb 2026. Median follow-up (N=22; ≥18 weeks follow up),

  11. Slide 11: ORR and DCR With Zoldonrasib + GnP

    ORR and DCR With Zoldonrasib + GnP in 1L RAS G12D PDAC Zoldonrasib 1200 mg QD + GnPa (N=31) ORR (95% CI), %b 61 (42–78) DCR (95% CI), %c 90 (74–98) • PFS and OS estimates remain immature due to limited follow-up at time of DCO Data cutoff: 8 Feb 2026. Median follow-up (N=31; ≥18 weeks follow up), mo

  12. Slide 12: ctDNA Molecular Response With Zoldonrasib + Chemotherapy

    ctDNA Molecular Response With Zoldonrasib + Chemotherapy in 1L RAS G12D PDAC Change in ctDNA RAS G12D VAF on Treatment (C2D1) On-Treatment ctDNA Molecular Response Rates Zoldonrasib Zoldonrasib Zoldonrasib Zoldonrasib + mFFX (N=17) + GnP (N=17) 1200 mg QD 1200 mg QD 100 + mFFX (N=17) + GnP (N=17) >5

  13. Slide 13: Conclusions

    Conclusions • The favorable safety and tolerability profile of zoldonrasib enables mean high dose intensities of 86% and 90% in combination with mFFX and GnP, respectively ‒ TRAEs were broadly consistent with the established profiles of mFFX and GnP • Zoldonrasib with chemotherapy showed compelling

  14. Slide 14: RASolute 305

    RASolute 305 Phase 3, Global, Double-Blind, Randomized Study of Zoldonrasib + Chemotherapy vs Placebo + Chemotherapy as 1L Treatment for Patients With KRAS G12D mPDAC (NCT07621718) Key Eligibility Criteria Zoldonrasib (1200 mg QD) + • Confirmed metastatic pancreatic mFOLFIRINOX or adenocarcinoma Gem

  15. Slide 15: Acknowledgments

    Acknowledgments • We thank all patients who participated in this study, their families who supported them, and the clinical investigators and research staff who cared for them • We also thank the Revolution Medicines Research and Development teams • The RMC-GI-102 study is sponsored by Revolution Me

Revolution Medicines — Technical Presentation (July 2026) on 6ix